Value Proposition Revenue Model

Recurring sensor-based revenue: Continuous glucose monitoring drives repeat sensor and transmitter sales, creating a consumables-led model with higher visibility than one-time device peers.

Integrated hardware-software workflow: The device, app, and data platform are sold as a connected system, supporting adoption and switching costs versus standalone diabetes device competitors.

Broad diabetes use-case coverage: Coverage across type 1 and type 2 diabetes expands the addressable base and reduces dependence on a single clinical segment.

Reimbursement-dependent monetization: Revenue capture still depends on payer access and coverage decisions, which makes growth less self-directed than software-like healthcare models.

Cost Structure

High gross-margin consumables mix: Recurring sensor replacement supports better unit economics than capital equipment models, improving margin resilience as installed base grows.

Meaningful R&D intensity: R&D at 12.4% of revenue indicates sustained product investment, which supports innovation but limits near-term operating margin expansion.

Moderate capital intensity: Capex at 7.3% of revenue suggests a manufacturing and supply-chain footprint that is scalable, but not asset-light.

Stock compensation dilution pressure: SBC at 3.5% of revenue is manageable, but it adds a recurring cost layer that slightly weakens true economic margin quality.

Scalability Operating Leverage

Installed-base leverage: Each new patient adds recurring sensor demand, so revenue can scale faster than fixed operating costs once commercial infrastructure is in place.

Manufacturing repeatability: Standardized sensor production supports volume leverage better than bespoke medical-device models with more complex customization.

Commercial scale benefits: A larger payer and provider footprint lowers incremental customer acquisition cost per user over time, improving operating leverage.

Product-cycle dependence: Periodic hardware and algorithm refreshes are required to sustain growth, which prevents the model from becoming fully self-expanding.

Customer Structure Concentration

Broad end-market base: Revenue is spread across many diabetes patients and care channels, reducing dependence on a small number of enterprise customers.

Payer concentration risk: Access is mediated by insurers and health systems, so reimbursement concentration can materially affect adoption and pricing power.

Channel dependence: Sales rely on healthcare providers, distributors, and payer pathways, which adds structural friction versus direct-to-consumer models.

Limited single-customer exposure: The model avoids large-account concentration, which improves resilience relative to medtech businesses tied to a few hospital buyers.

Revenue Quality Predictability

High repeat purchase frequency: Sensor replacement creates recurring demand, making revenue more predictable than durable-goods medical devices.

Usage-linked visibility: Revenue tracks patient utilization rather than discretionary replacement cycles, improving short- to medium-term forecasting.

Reimbursement and adoption variability: Revenue quality is still exposed to payer policy changes and patient onboarding rates, which can create quarter-to-quarter volatility.

Better predictability than peers: Compared with many medtech peers, the consumables-led CGM model offers stronger recurring visibility and lower demand lumpiness.

Overall Score

DXCM has a strong consumables-led CGM model with recurring revenue, scalable installed-base economics, and better predictability than most medtech peers, but reimbursement dependence limits structural control.

Score Driver: Recurring Sensor Replacement Tied To A Growing Installed Base Is The Dominant Structural Driver Of Revenue Visibility And Operating Leverage.